

# Author's Accepted Manuscript

Efficacy and Safety of SER120 Nasal Spray in Nocturia Patients Pooled Analysis of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

Jed Kaminetsky , Seymour Fein , Roger Dmochowski , Scott MacDiarmid , Steven Abrams , Maria Cheng , Alan Wein



PII: S0022-5347(18)42971-0  
DOI: [10.1016/j.juro.2018.04.050](https://doi.org/10.1016/j.juro.2018.04.050)  
Reference: JURO 15558

To appear in: *The Journal of Urology*  
Accepted Date: 6 April 2018

Please cite this article as: Kaminetsky J, Fein S, Dmochowski R, MacDiarmid S, Abrams S, Cheng M, Wein A, Efficacy and Safety of SER120 Nasal Spray in Nocturia Patients Pooled Analysis of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials, *The Journal of Urology*® (2018), doi: 10.1016/j.juro.2018.04.050.

**DISCLAIMER:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

## Embargo Policy

**All article content is under embargo until uncorrected proof of the article becomes available online.**

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to [jumedia@elsevier.com](mailto:jumedia@elsevier.com).

## Efficacy and Safety of SER120 Nasal Spray in Nocturia Patients

### Pooled Analysis of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

Jed Kaminetsky,\* Seymour Fein, Roger Dmochowski, Scott MacDiarmid, Steven Abrams, Maria Cheng and Alan Wein

*From NYU Medical Center, New York, New York (JK), Serenity Pharmaceuticals LLC, Milford, Pennsylvania (SF), Vanderbilt University, Nashville, Tennessee (RD), Alliance Urology Specialists, Greensboro, North Carolina (SM), Allergan plc, Irvine, California (SA), Serenity Pharmaceuticals LLC, Milford, Pennsylvania (MC) and University of Pennsylvania, Philadelphia, Pennsylvania (AW)*

**\*Correspondence:** Jed Kaminetsky, MD, Department of Urology, NYU Medical Center, 215 Lexington Avenue 20th Floor, New York, NY 10016 (telephone: 212-686-9015; e-mail: [jckammd@att.net](mailto:jckammd@att.net)).

[SF] Serenity Pharmaceuticals LLC, Milford, Pennsylvania. E-mail: [sfein@serenitypharma.com](mailto:sfein@serenitypharma.com)

[RD] Vanderbilt University, Nashville, Tennessee. E-mail: [roger.dmochowski@Vanderbilt.Edu](mailto:roger.dmochowski@Vanderbilt.Edu)

[SM] Alliance Urology Specialists, Greensboro, North Carolina. E-mail:

[smacdiarmid@allianceurology.com](mailto:smacdiarmid@allianceurology.com)

[SA] Allergan plc, Irvine, California. E-mail: [abrams\\_steve@allergan.com](mailto:abrams_steve@allergan.com)

[MC] Serenity Pharmaceuticals LLC, Milford, Pennsylvania. E-mail:

[mcheng@serenitypharma.com](mailto:mcheng@serenitypharma.com)

[AW] University of Pennsylvania, Philadelphia, Pennsylvania. E-mail:

[alan.wein@uphs.upenn.edu](mailto:alan.wein@uphs.upenn.edu)

Download English Version:

<https://daneshyari.com/en/article/8770426>

Download Persian Version:

<https://daneshyari.com/article/8770426>

[Daneshyari.com](https://daneshyari.com)